US Bancorp’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-41,605
Closed -$749K 3947
2020
Q2
$749K Sell
41,605
-5,747
-12% -$79.9K ﹤0.01% 1092
2020
Q1
$338K Buy
47,352
+844
+2% +$10.5K ﹤0.01% 1404
2019
Q4
$1.11M Sell
46,508
-90
-0.2% -$2.48K ﹤0.01% 1013
2019
Q3
$1.25M Sell
46,598
-1,920
-4% -$53.9K ﹤0.01% 935
2019
Q2
$1.32M Buy
48,518
+199
+0.4% +$6.24K ﹤0.01% 960
2019
Q1
$1.68M Buy
48,319
+4,185
+9% +$121K ﹤0.01% 842
2018
Q4
$862K Buy
44,134
+2,530
+6% +$52K ﹤0.01% 1087
2018
Q3
$1.11M Sell
41,604
-812
-2% -$26.5K ﹤0.01% 1048
2018
Q2
$1.6M Sell
42,416
-2,203
-5% -$84.3K ﹤0.01% 894
2018
Q1
$1.46M Buy
44,619
+829
+2% +$36.4K ﹤0.01% 917
2017
Q4
$2.13M Buy
43,790
+941
+2% +$47.6K 0.01% 766
2017
Q3
$2.31M Buy
42,849
+1,695
+4% +$99.5K 0.01% 737
2017
Q2
$2.31M Buy
41,154
+48
+0.1% +$1.92K 0.01% 710
2017
Q1
$1.61M Buy
41,106
+106
+0.3% +$3.38K 0.01% 862
2016
Q4
$920K Sell
41,000
-500
-1% -$9.77K ﹤0.01% 1106
2016
Q3
$943K Buy
41,500
+500
+1% +$11.7K ﹤0.01% 1055
2016
Q2
$968K Hold
41,000
﹤0.01% 1023
2016
Q1
$836K Hold
41,000
﹤0.01% 1073
2015
Q4
$2.11M Hold
41,000
0.01% 686
2015
Q3
$1.75M Buy
41,000
+20,000
+95% +$965K 0.01% 741
2015
Q2
$957K Buy
21,000
+11,000
+110% +$443K ﹤0.01% 1047
2015
Q1
$380K Buy
+10,000
New +$343K ﹤0.01% 1487

US Bancorp's PTLA Position: Q3 2020 in Review

US Bancorp sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 41,605 shares — an estimated $749K sold.

US Bancorp first reported a position in PTLA in Q1 2015 and held it in 22 quarters. The position peaked at $2.31M in Q3 2017. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

  • US Bancorp reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • US Bancorp sold 41,605 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $749K.
  • US Bancorp first reported a position in Portola Pharmaceuticals, Inc. in Q1 2015 and held it in 22 quarters.
  • US Bancorp's Portola Pharmaceuticals, Inc. position peaked at $2.31M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on US Bancorp's 13F filing for Q3 2020, filed 10 Nov 2020.